Clinical trial
XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic…
NCT00215722 · Grupo de Investigacao do Cancro Digestivo, Other · Unknown status
Key facts
| NCT number | NCT00215722 |
|---|---|
| Title | XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer |
| Lead sponsor | Grupo de Investigacao do Cancro Digestivo, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Carcinoma |
| Intervention type | Drug |
| Interventions | Cetuximab |
| Enrollment | 45 |
| Start date | Jul 1, 2005 |
| Completion | Jul 1, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 6, 2007 |
| Countries | Portugal |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: